secwatch.observer — SEC 8-K summary
======================================

Issuer:     Regulus Therapeutics Inc. (—)
CIK:        0001505512
Form:       8-K
Filed at:   2024-05-17T23:59:59+00:00
Accession:  0001193125-24-141703
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares
--------------------------------------------------------------------------

- Amendment increases share reserve by 9.5M shares; total authorized now 18,574,542.
- Vote: 32,563,555 for, 5,916,084 against, 29,301 abstentions, 3,688,130 broker non-votes.
- Automatic annual increase formula changed to include shares from convertible preferred and prefunded warrants.
- All 10 director nominees elected; say-on-pay approved; Ernst & Young ratified as auditor.
- Non-binding say-on-pay frequency set at one year, consistent with board recommendation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/d829869d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-141703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer